Braingaze

Braingaze operates at the intersection of digital therapeutics, neurodiagnostics, eye tracking, and AI-assisted clinical decision support. Its stated focus is narrower than broad mental-health software: the company targets ADHD, autism, dyslexia, and cognitive impairment using involuntary eye-movement biomarkers captured during functional games. BGaze Clinic is positioned as a diagnostic-support and monitoring platform, while BGaze Focus extends the model into mobile, drug-free therapeutic experiences. This combination gives Braingaze a differentiated product architecture because assessment, intervention, and monitoring are addressed within the same clinical theme rather than as separate point solutions. The company also cites CE marking for its medical-device tools, an important commercialization signal in Europe. Its small employee band of one to ten people and approximately $1.63 million in disclosed cumulative funding suggest an early commercial position rather than scale leadership. Competitive strength therefore depends on biomarker validation, clinical adoption, reimbursement, and evidence that its game-based approach improves engagement and outcomes.

Braingaze has followed a long, research-to-commercialization trajectory since its founding on Sep 9, 2013 as a University of Barcelona spin-off. The financing history shows four rounds across a decade: pre-seed in 2014, equity crowdfunding in 2016, seed funding in 2020, and a $1.63 million venture round announced on Mar 6, 2024. The 2024 round is the main inflection point because it followed the development of CE-marked medical-device tools and was described as funding the move toward bringing cognitive-health solutions to market. Earlier coverage of a €336,000 raise in 2014 indicates that the company began with modest early-stage capital, while the 2020 seed round added Orbit Ventures, SOSV, and Chinaccelerator to its investor base. Product development has expanded from eye-movement biomarker research into two defined offerings: BGaze Clinic for diagnostic support and BGaze Focus for mobile digital therapy. The trajectory remains constrained by limited disclosed hiring, a current employee band of one to ten, and no reported follow-on round or major launch after 2024. Growth will likely depend on converting clinical validation and regulatory positioning into recurring healthcare adoption.